FREE Webinar
Wednesday, May 19, 2021
12:00 - 1:00 PM Eastern Time
For scientific and diagnostic laboratories, a secure supply chain for high-quality reagents is critical for weathering unforeseen circumstances such as the COVID-19 pandemic. Historically, recombinant antibody technology has been reserved for companies developing novel biologics. The technology mitigates manufacturing and supply risks by “digitizing” antibody assets and guaranteeing long-term reproducible production. Recombinant technology also increases the ability to engineer existing antibodies for any specific bio-physical requirements that might arise, as producing antibodies by transient transfection enables rapid reformatting.
In this webinar brought to you by Sartorius, Nicholas Hutchings will describe how recombinant antibody technology came to the rescue during the COVID-19 pandemic. COVID-19 antibodies were quickly produced and tested in a variety of formats so that researchers would have the tools they needed to investigate the virus and develop diagnostic assays and treatments. This process can ...
